key: cord-0960233-9rs91vfr
authors: Storlie, Curtis B.; Pollock, Benjamin D.; Rojas, Ricardo L.; Demuth, Gabriel O.; Johnson, Patrick W.; Wilson, Patrick M.; Heinzen, Ethan P.; Liu, Hongfang; Carter, Rickey E.; Habermann, Elizabeth B.; Kor, Daryl J.; Neville, Matthew R.; Limper, Andrew H.; Noe, Katherine H.; Bydon, Mohamad; Franco, Pablo Moreno; Sampathkumar, Priya; Shah, Nilay D.; Dunlay, Shannon M.; Dowdy, Sean C.
title: Quantifying the Importance of COVID-19 Vaccination to Our Future Outlook
date: 2021-04-27
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.04.012
sha: 05316bc0c17f2dbbbf29fd98cdc89c8a0271bf23
doc_id: 960233
cord_uid: 9rs91vfr

Predictive models have played a critical role in local, national, and international response to the COVID-19 pandemic. In the U.S, health care systems and governmental agencies have relied on several models such as IHME, YYG, MIT, CDC ensemble, etc. to predict short and long-term trends in disease activity. The Mayo Clinic Bayesian SIR model, recently been made publicly available, has informed Mayo Clinic practice leadership at all sites across the US and has been shared with Minnesota governmental leadership to help inform critical decisions over the past year. One key to the accuracy of the Mayo model is its ability to adapt to the constantly changing dynamics of the pandemic and uncertainties of human behavior, such as changes in the rate of contact among the population over time and by geographic location and now new virus variants. The Mayo model can also be used forecast COVID-19 trends in different hypothetical worlds in which (i) no vaccine is available, (ii) vaccinations are no longer being accepted from this point forward, and (iii) 75% of the population is already vaccinated. Surveys indicate that half of American adults are hesitant to receive a COVID-19 vaccine, and lack of understanding of the benefits of vaccination is an important barrier to use. The focus of this paper is to illustrate the stark contrast between these three scenarios and to demonstrate, mathematically, the benefit of high vaccine uptake on the future course of the pandemic.

The rapid development and availability of vaccines has had a significant impact on the potential to control the COVID-19 pandemic. Currently, there are three vaccines approved by the Food and Drug Administration (FDA) with emergency use authorization in the United States. With the potential concerns around vaccine hesitancy, it would be valuable to understand the impact of different levels of vaccination rates on controlling the pandemic. Various modeling approaches may be used to better understand the impact of vaccination on infection rates. Predictive models have played a critical role in local, national, and international response to the COVID-19 pandemic. In the U.S, health care systems and governmental agencies have relied on several models such as IHME (COVID IHME, 2020), YYG (Gu, Y., 2021), MIT (Kissler et al., 2020) , and CDC ensemble (Ray et al., 2020) to predict short and long-term trends in disease activity. In this paper, we use the Mayo Clinic Bayesian SIR model to compare three vaccine uptake scenarios on the future course of the pandemic. The Mayo Clinic Bayesian SIR model was recently made available to the public (Storlie et al., 2021) . This model has been used by practice leadership at all Mayo hospitals across the country to safely manage patient volumes and has been shared with Minnesota state leadership to help inform critical decisions over the writing) under our best guess for vaccinations going forward. The vaccination model is described in the Supplemental Material, but essentially assumes that future vaccination trends will be similar to the past few weeks until we reach a point of dwindling demand (when 50 to 75% of the population has been vaccinated). These results suggest that the current rise in COVID cases in MN is likely to continue for a few more weeks before decreasing into the summer. The interquartile range (dashed lines) and the 90% Bayesian credible interval (CI) J o u r n a l P r e -p r o o f indicate bounds that should contain the future trend with 50% and 90% certainty respectively.

Based on prospective validation, the Bayes SIR model has been very accurate with its probability statements representing this uncertainty. Namely, very close to 50% of future paths for cases and hospitalizations have fallen within the predictive IQR for time horizons up to 4 weeks and similar for the 90% bounds (Storlie et al., 2021) . These bounds indicate that a large rise approaching the magnitude of cases observed in November/December 2020 is possible, even if unlikely. It is also possible that cases and hospitalizations will stop increasing immediately and begin to fall off much sooner, although this is also unlikely.

In this section three hypothetical vaccination scenarios are considered. While none of these scenarios are realistic, they serve to illustrate the critical impact of vaccination rates on COVID-19 cases and hospitalizations.

The first scenario depicted in Figure 2 shows a hypothetical future in which a COVID-19 vaccine did not exist under our current behavior patterns with current strains of the virus. For a given county and day, the model estimates a rate of spread for a given infected individual if all people were susceptible, but then suppresses that rate by the proportion of the population that is not currently susceptible to infection. This model estimate for the (unabated) rate of spread can change due to new variants and/or changes in social behavior. To produce the "no vaccine" scenario, we simply placed the vaccinated individuals back into the susceptible pool and propagated the model forward with no impedance to the rate of spread due to vaccination).

However, it is still assumed there is impedance due to natural infection acquired immunity.

The rise under this scenario is stark and almost unbelievable. This is because the actual rise that is currently happening in MN is in the face of a ~35% vaccinated population (according to CDC data), which means the (unabated) spread rate in the model right now is very high. That is, if no one were vaccinated, we would likely be seeing a much higher reproduction number right now than we have seen since very early on in the pandemic. It is difficult to untangle how much of this elevated rate of spread right now is due to new variants as opposed to changes in social behavior. Regardless of the reason, the absence of vaccinations in the current environment would have been likely to result in by far the largest surge to date.

Thankfully, we do have several effective vaccines that people are receiving. As of this writing, according to CDC data, 33% of the US population has received at least one dose of vaccine (CDC, 2021). The second hypothetical scenario examines resulting cases and hospitalizations in the event that no further vaccinations are given (Figure 3 ). Our model demonstrates that existing vaccinations are substantially blunting the rise predicted in Figure 2 .

However, without further vaccinations, the risk of a substantial increase is much greater and would last much longer than what is expected under our "best guess" scenario presented in Edridge et al., 2020) with some becoming susceptible again to infection sooner than others. This time frame also depends greatly on impact of new virus variants on vaccine efficacy. It is also understood that the fewer cases there are, the less opportunity that the SARS-CoV-2 virus has to mutate and generate new strains that can escape vaccine induced immunity. (3) The vaccine is not 100% effective, even in the next few months after receiving it, so it will not prevent all infections and this is considered in the modeling results above. However, vaccination has also been shown to decrease the severity of infections and potential need for hospitalizations. 

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19≥ 7 days after the 2nd dose

Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries. medRxiv

Seasonal coronavirus protective immunity is shortlasting. Nature medicine

Covid-19 projections using machine learning

Willingness to get the COVID-19 vaccine with and without emergency use authorization

Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of'real-world'vaccination outcomes from Israel

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Doing Bayesian data analysis: A tutorial with

Immunological characteristics govern the transition of COVID-19 to endemicity

Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Ensemble Forecasts of Coronavirus Disease 2019 (COVID-19) in the us

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet

What we know about covid-19 reinfection so far. bmj

A Hierarchical Bayesian Model for Stochastic Spatiotemporal SIR Modeling and Prediction of COVID-19 Cases and Hospitalizations

National Trends in the US Public's Likelihood of Getting a COVID-19 Vaccine

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet